Results 51 to 60 of about 29,030 (239)
Neurodegenerative Disease Management, 2022 Aims: Natalizumab is approved as an infusion every 4 weeks (standard-interval dosing [SID]) in relapsing-remitting multiple sclerosis (MS). Extended-interval dosing (EID) reduces risk of progressive multifocal leukoencephalopathy (PML) compared with SID,
M. Moccia +9 more
semanticscholar +1 more source
The role of natalizumab in the treatment of multiple sclerosis: benefits and risks
Therapeutic Advances in Neurological Disorders, 2017 Natalizumab, a monoclonal antibody that blocks lymphocyte infiltration in the central nervous system, is a valuable tool in the treatment of relapsing forms of multiple sclerosis (MS). In a phase III clinical trial comparing natalizumab with placebo over
Barry A. Singer
doaj +1 more source
A programme for risk assessment and minimisation of progressive multifocal leukoencephalopathy developed for vedolizumab clinical trials [PDF]
, 2018 Introduction Over the past decade, the potential for drug-associated progressive multifocal leukoencephalopathy (PML) has become an increasingly important consideration in certain drug development programmes, particularly those of immunomodulatory ...
Berger, Joseph R +12 more
core +3 more sources
Self-Limited Cytomegalovirus Infection During Natalizumab Treatment for Multiple Sclerosis
European Journal of Case Reports in Internal Medicine, 2019 Natalizumab is indicated as monotherapy for the treatment of relapsing-remitting multiple sclerosis; it prevents outbreaks and delays the progression of physical disability.
Marina Rodrigues Lima +3 more
doaj +1 more source
T Helper Cells: The Modulators of Inflammation in Multiple Sclerosis [PDF]
, 2020 Multiple sclerosis (MS) is a chronic neurodegenerative disease characterized by the progressive loss of axonal myelin in several areas of the central nervous system (CNS) that is responsible for clinical symptoms such as muscle spasms, optic neuritis ...
Amormino, Carola +4 more
core +1 more source
Neurology, 2021 Background and Objectives To investigate the potential of serum neurofilament light (NfL) to reflect or predict progression mostly independent of acute inflammatory disease activity in patients with relapsing-remitting multiple sclerosis (RRMS) treated ...
C. Bridel +10 more
semanticscholar +1 more source
Clinical and Translational Medicine, 2018 Multiple sclerosis (MS) is a progressive immune-related disorder of the central nervous system leading to destruction of myelin sheaths. Natalizumab is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin which has been approved
Mehrdokht Mazdeh +3 more
doaj +1 more source
Induced Stem Cells as a Novel Multiple Sclerosis Therapy. [PDF]
, 2016 Stem cell replacement is providing hope for many degenerative diseases that lack effective therapeutic methods including multiple sclerosis (MS), an inflammatory demyelinating disease of the central nervous system. Transplantation of neural stem cells or
Guan, Yang-Tai +3 more
core +2 more sources
Relapse-independent multiple sclerosis progression under natalizumab
Brain Communications, 2021 The objective of this study was to investigate confirmed progression independent of relapse activity in relapsing-remitting multiple sclerosis patients under long-term natalizumab treatment. We performed a retrospective, cross-sectional study of clinical
Jonas Graf +10 more
semanticscholar +1 more source
Dynamic changes of mmp-9 plasma levels correlate with jvc reactivation and immune activation in natalizumab-treated multiple sclerosis patients [PDF]
, 2019 The aim of the study was to investigate the changes of matrix metalloproteinase (MMP)-2 and MMP-9 plasma levels during natalizumab treatment and their correlation with JC virus (JCV) reactivation and T-lymphocyte phenotypic modifications in peripheral ...
Ciardi, Maria Rosa +14 more
core +3 more sources